OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

July 5th 2019

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Karmali on the Toxicity Profile of Ibrutinib Maintenance in MCL

July 4th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLC

July 4th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Cowan on Treatment Strategies in Transplant Eligible- and -Ineligible Myeloma

July 4th 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses treatment strategies for patients with transplant-eligible and -ineligible multiple myeloma.

Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials

July 4th 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Dr. Richardson Discusses the FDA Approval of Selinexor in Myeloma

July 3rd 2019

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the FDA approval of selinexor in multiple myeloma.

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

July 3rd 2019

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Dr. Polsky on Using ctDNA as a Biomarker for Melanoma

July 2nd 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC

July 2nd 2019

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 2nd 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers

July 2nd 2019

Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.

Dr. Fertrin on the FDA Approval of Avatrombopag in ITP

July 2nd 2019

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the FDA approval of avatrombopag in immune thrombocytopenia (ITP).

Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL

July 2nd 2019

Enrico Tiacci, MD, discusses safety and efficacy results of a trial evaluating the BRAF inhibitor vemurafenib combined with rituximab in hairy cell leukemia.

Dr. Lennes on Aspects of Lung Cancer Screening

June 28th 2019

Inga T. Lennes, MD, MBA, MPH, medical director, Ambulatory Services, director of clinical quality, Massachusetts General Hospital Cancer Center, discusses aspects of lung cancer screening.

Dr. Shadman on Challenges With CAR T-Cell Therapy

June 28th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

Dr. Choudhury on Targeted Therapy in Prostate Cancer

June 28th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLC

June 28th 2019

Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.

Experts Highlight Ongoing Research Efforts Across Tumor Types

June 28th 2019

OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.

Dr. McGregor on the Goal of the PRONOUNCE Trial in Prostate Cancer

June 28th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the hope for the phase IIb PRONOUNCE trial in prostate cancer.